KR101986832B1 - Composition for preventing or treating spinal cord injury comprising α-asarone - Google Patents
Composition for preventing or treating spinal cord injury comprising α-asarone Download PDFInfo
- Publication number
- KR101986832B1 KR101986832B1 KR1020170129118A KR20170129118A KR101986832B1 KR 101986832 B1 KR101986832 B1 KR 101986832B1 KR 1020170129118 A KR1020170129118 A KR 1020170129118A KR 20170129118 A KR20170129118 A KR 20170129118A KR 101986832 B1 KR101986832 B1 KR 101986832B1
- Authority
- KR
- South Korea
- Prior art keywords
- spinal cord
- asarone
- cord injury
- alpha
- pharmaceutical composition
- Prior art date
Links
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 title claims abstract description 61
- 208000020431 spinal cord injury Diseases 0.000 title claims abstract description 42
- 239000000203 mixture Substances 0.000 title abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 32
- 208000014674 injury Diseases 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 17
- 230000036541 health Effects 0.000 claims description 10
- 239000004480 active ingredient Substances 0.000 claims description 9
- 230000008733 trauma Effects 0.000 claims description 8
- 235000013376 functional food Nutrition 0.000 claims description 5
- 208000030527 Minamata disease Diseases 0.000 claims description 3
- 208000009507 Nervous System Mercury Poisoning Diseases 0.000 claims description 3
- 208000018254 acute transverse myelitis Diseases 0.000 claims description 3
- 208000002040 neurosyphilis Diseases 0.000 claims description 3
- 230000010287 polarization Effects 0.000 claims description 3
- 208000009174 transverse myelitis Diseases 0.000 claims description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000003906 hydrocephalus Diseases 0.000 claims description 2
- 239000006186 oral dosage form Substances 0.000 claims description 2
- 239000006201 parenteral dosage form Substances 0.000 claims description 2
- 206010003591 Ataxia Diseases 0.000 claims 3
- 208000003926 Myelitis Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000000278 spinal cord Anatomy 0.000 abstract description 30
- 239000003814 drug Substances 0.000 abstract description 17
- 230000000694 effects Effects 0.000 abstract description 15
- 229940079593 drug Drugs 0.000 abstract description 9
- 238000011084 recovery Methods 0.000 abstract description 6
- 208000027866 inflammatory disease Diseases 0.000 abstract description 4
- 230000007659 motor function Effects 0.000 abstract description 4
- 239000000825 pharmaceutical preparation Substances 0.000 abstract description 4
- 230000000144 pharmacologic effect Effects 0.000 abstract description 4
- 230000002411 adverse Effects 0.000 abstract description 3
- 229940126534 drug product Drugs 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract description 2
- 231100000419 toxicity Toxicity 0.000 abstract description 2
- 230000006378 damage Effects 0.000 description 20
- 208000027418 Wounds and injury Diseases 0.000 description 13
- 235000013305 food Nutrition 0.000 description 13
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 8
- 102100025136 Macrosialin Human genes 0.000 description 8
- -1 inorganic acid salt Chemical class 0.000 description 8
- 238000010186 staining Methods 0.000 description 7
- 210000000115 thoracic cavity Anatomy 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 6
- 101150088826 arg1 gene Proteins 0.000 description 6
- 238000011532 immunohistochemical staining Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 5
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 5
- 101100379633 Xenopus laevis arg2-a gene Proteins 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 238000001604 Rao's score test Methods 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100034594 Angiopoietin-1 Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241001269524 Dura Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 206010041549 Spinal cord compression Diseases 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 108091008605 VEGF receptors Proteins 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- RCPWCRFPCOXJBQ-UHFFFAOYSA-N 2-acetamido-3-[4-[bis(2-chloroethyl)amino]phenyl]-n-(1,3-thiazol-2-yl)propanamide Chemical compound N=1C=CSC=1NC(=O)C(NC(=O)C)CC1=CC=C(N(CCCl)CCCl)C=C1 RCPWCRFPCOXJBQ-UHFFFAOYSA-N 0.000 description 2
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010015548 Euthanasia Diseases 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 2
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 2
- 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102100040247 Tumor necrosis factor Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LWMSKKORNYUDIK-HBVWGTQWSA-N 1,2,4-trimethoxy-5-[(E)-prop-1-enyl]benzene Chemical compound COC1=CC(OC)=C(\C=C\C)C=C1OC.COC1=CC(OC)=C(\C=C\C)C=C1OC LWMSKKORNYUDIK-HBVWGTQWSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 241000209495 Acorus Species 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical class N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010048154 Angiopoietin-1 Proteins 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 101100008044 Caenorhabditis elegans cut-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 244000017020 Ipomoea batatas Species 0.000 description 1
- 235000002678 Ipomoea batatas Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 101100260702 Mus musculus Tinagl1 gene Proteins 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102000007072 Nerve Growth Factors Human genes 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 208000030304 gastrointestinal bleeding Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 201000003636 hereditary ataxia Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- HSSGNVITVKZRHD-UHFFFAOYSA-L magnesium octadecanoate octadecanoic acid Chemical compound [Mg++].CCCCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HSSGNVITVKZRHD-UHFFFAOYSA-L 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000013223 sprague-dawley female rat Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a composition for preventing or treating spinal cord injury comprising alpha asarone. Alpha-asarone according to the present invention has an effect of enhancing motor function or promoting recovery of injured spinal cord when administered to spinal cord injured individuals, and thus may be useful for preventing, improving or treating inflammatory diseases and spinal cord injuries. In addition, Alpha Asarone is a registered herb medicine ingredient in the Korea Food and Drug Administration and has a low risk of adverse effects. Therefore, it is easy to carry out clinical trials because it is exempted from the nonclinical toxicity and pharmacological test results when obtaining the approval of the drug product.
Description
The present invention relates to a composition for preventing or treating spinal cord injury comprising alpha asarone.
Spinal cord injury is one of the most common accidents in adults. According to US statistics, there are 2,500,000 patients worldwide, 130,000 patients each year, and the annual incidence of patients is increasing. These statistics are not exceptions in Korea. According to National Health Insurance Corporation analysis of health insurance fee payment data from 2013 to 2014, about 800 patients were born and this trend continued to increase. In particular, the degree of loss to individuals and society is very serious, as the disease occurs in the form of trauma from relatively young patients.
Damage to the spinal cord is a secondary regression that leads to mechanical damage and consequent loss of tissue progression. The pathologic phenomenon that occurs after spinal cord injury is classified into two stages, primary damage and secondary damage, over time. Primary injury occurs within minutes after traumatic injury, and necrosis of cell death occurs mainly in wound area. The cause of this reaction is mediated inflammatory reaction induced mainly by pro-inflammatory cytokine. Secondary damage following primary injury progresses slowly from hours to days and not only the cells in the wound area die, but also the surrounding neurons gradually undergo apoptosis. Inflammatory responses from primary damage are a major mechanism of these secondary injuries and are involved in causing neuropathies of chronic spinal cord injury. As the inflammatory reaction continues, apoptosis gradually enlarges and the damaged area inside the spinal cord becomes wider, resulting in a permanent loss of function.
Currently, the direction of spinal cord injury treatment is to minimize the damage of the secondary spinal cord and restore the neurological function to its maximum extent. First, if a spinal cord injury occurs, there is a method of preventing cell necrosis due to the inflammation reaction of neurons using a high-dose steroid drug while eliminating the fragment or dislocation that compresses the spinal cord through surgical treatment. However, administration of steroid drugs to patients at high doses has limited clinical efficacy because of the enormous side effects of sepsis, gastrointestinal bleeding, and pneumonia. Because of the above reasons, there is no stable therapeutic agent that can restore the damaged spinal nerve. That is, there is a need for a therapeutic agent capable of treating spinal cord injury, having potent anti-inflammatory activity without side effects.
One aspect is to provide a pharmaceutical composition for preventing or treating spinal cord injury comprising alpha-asarone or a pharmaceutically acceptable salt thereof as an active ingredient.
Another aspect is to provide a health functional food for preventing or ameliorating spinal cord injury comprising alpha-asarone as an active ingredient.
One aspect provides a pharmaceutical composition for preventing or treating spinal cord injury comprising an essential oil component of Acorus gramineus , for example, alpha-asarone or a pharmaceutically acceptable salt thereof as an active ingredient.
The term "seokchangpo" is the scientific name Acorus It is a gramineus , a perennial plant with green leaves of the genus Agate . The rootstock is thick and hard, has many nodes, and is attached to the same spot as a rock gap by taking out roots. Leaves grow from roots to base layers overlapping each other. Narrow strips are brittle and shiny. The tip of the leaf is pointed like a knife, the edge is plain and always smells good. Flowers blend in the shape of a round stick in the middle of the flower-like peduncle. The length of the stick is 5cm and the color is yellowish blue. It is also called white whitish, iris, stony grass and gypsum, and it contains 0.5 ~ 0.8% essential oil in rootstock. Essential oils are Asarone, Palmitinsaure and Phenol.
In the present specification, the term "alpha asarone" may be mixed with "asarone ", and may be a compound represented by the following formula (1).
Alpha-asarone inhibits neuroinflammation through inhibition of various inflammatory factors such as TNF-α, IL-1beta and IL-6, as well as neuroprotection through antioxidative and nitric oxide inhibitory effects in various parts of the brain The effect can be shown. Since the initial mechanism of spinal cord injury is so fast that it is difficult to treat it as a pharmacologic treatment, the pharmacological strategies dealing with the secondary mechanism are an important part of the development of therapeutic agents. In this regard, up to now, steroids, antioxidants, glutamate receptor inhibitors, A variety of potential pharmacological treatments have been attempted, including inhibitors, gangliosides, antibodies to axon regeneration inhibitors, antiinflammatory agents, and neurotrophins. However, the alpha-asarone has not been studied in the spinal cord injury study so far. Therefore, the pharmaceutical composition for preventing or treating spinal cord injury according to the present invention is useful as an anti-inflammatory, M2 polarizaton and anti- It was confirmed whether or not the effect of angiogenesis could be shown.
Since the alpha asarone has been confirmed as the present invention that can effectively treat damaged spinal cord without side effects, the pharmaceutical composition according to the present invention can be used not only as a spinal cord injury due to trauma, but also as a spinal cord injury-related acute transverse myelitis, , Hereditary diseases, non-Hodgkin's lymphoma, hydrocephalus, hereditary ataxia, neurosyphilis, Minamata disease, Lou Gehrig's disease, multiple sclerosis and the like.
The alpha asarone may be included in the composition as a pharmaceutically acceptable salt thereof. The salt may be an acid addition salt or a base addition salt. The acid addition salt includes a salt with an inorganic acid or an organic acid. Examples of the inorganic acid salt include salts with hydrochloric acid, hydrobromic acid, phosphoric acid or sulfuric acid. Examples of the organic acid salt include acetic acid, trifluoroacetic acid, propionic acid, maleic acid, fumaric acid, malic acid, citric acid, , Benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid or naphthalenedisulfonic acid, but is not limited thereto. The base addition salts include, for example, alkali metal salts such as sodium or potassium salts, alkaline earth metal salts such as calcium or magnesium salts, or ammonia salts or organic amine salts such as diethylamine, triethylamine, ethyl And salts with diisopropylamine, procaine, dibenzylamine, N-methylmorpholine, or dihydroabiethylamine.
As used herein, alpha asanone or a pharmaceutically acceptable salt thereof is to be interpreted to be in any form selected from the group consisting of any of its crystalline forms and amorphous forms, and hydrates, solvates, and co-crystals thereof.
The pharmaceutical composition according to the present invention may be an oral or parenteral dosage form. The pharmaceutical preparations may be formulated for oral administration, such as tablets, hard or soft capsules, liquids, suspensions, etc. These pharmaceutical preparations may contain conventional pharmaceutically acceptable carriers, for example, excipients, binders , A disintegrant, a lubricant, a solubilizing agent, a suspending agent, a preservative or an extender, and the like. In addition, the pharmaceutical composition may be used as a preparation for parenteral administration such as cream, gel, patch, spray, ointment, warning agent, lotion and the like.
The pharmaceutical composition may further contain commonly used excipients, disintegrants, sweeteners, lubricants, flavors and the like, and may be formulated into tablets, capsules, powders, granules, suspensions, emulsions, syrups, Other liquid formulations may be formulated.
Binders such as lactose, saccharose, sorbitol, mannitol, starch, amylopectin, celluloses or gelatin, excipients such as dicalcium phosphate, disintegrants such as corn starch or sweet potato starch, and disintegrants such as stearic acid Magnesium stearate, calcium stearate, sodium stearyl fumarate, or polyethylene glycol wax. In the case of a capsule formulation, in addition to the above-mentioned substances, a liquid carrier such as fatty oil is contained.
In addition, the pharmaceutical composition of the present invention can be administered orally or parenterally. For parenteral administration, subcutaneous injection, intravenous injection, intramuscular injection, or intramuscular injection can be selected. For formulation into parenteral administration formulations, the bile acid or the salt thereof of the present invention is mixed with water or a stabilizer or buffer to prepare a suspension, which is then formulated into a unit dosage form of ampoule or vial.
As used herein, the term "administering " means introducing the pharmaceutical composition of the present invention into an inflammatory disease or a suspect member of spinal cord injury by any appropriate method, and the administration route may be either oral or parenteral May be administered via various routes of administration.
The pharmaceutical compositions herein may be administered in a pharmaceutically effective amount.
As used herein, the term "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and the effective dose level will vary depending on the species and severity, age, sex, The type of drug, the activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and the rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents, and may be administered sequentially or simultaneously with conventional therapeutic agents. And can be administered singly or multiply. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art. The dosage of the pharmaceutical composition of the present invention may be determined by a specialist depending on various factors such as the condition of the patient, age, sex, and complications, but is generally from 0.1 mg to 10 g per kg of the adult, or from 10 mg to 5 g Dose. ≪ / RTI > Also, the daily dosage of the pharmaceutical composition per unit dosage form, or a half, 1/3, or 1/4 dose thereof, may be contained, and may be administered 1 to 6 times per day. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of controlling health, the amount may be less than the above range, and the active ingredient may be used in an amount of more than the above range since there is no problem in terms of safety.
In one embodiment, the alpha asarone may be one that causes M2 polarization.
In addition, the alpha asarone may be one that inhibits the expression of inflammatory cytokine genes and proteins. The inflammatory cytokine may be at least one selected from the group consisting of TNF-a, IL-1 alpha, IL-1 beta, and IL-6.
In another embodiment, the alpha asarone may be one that enhances the motor function of the spinal cord injured entity, or promotes repair of damaged spinal cord tissue.
Thus, alpha asarone or a pharmaceutically acceptable salt thereof according to one embodiment may be usefully employed in compositions for the prevention, amelioration, or treatment of inflammatory diseases or spinal cord injury.
Another aspect provides a health functional food for preventing or ameliorating spinal cord injury comprising alpha-asarone as an active ingredient.
The food may be, but is not limited to, a health supplement food, a health functional food, a functional food, and the like, and includes the addition of the compound of the present invention to natural foods, processed foods, patient foods, and general food ingredients.
The food composition according to the present invention can be used as it is, or can be used in combination with other food or food compositions, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to its intended use (prevention, improvement, or therapeutic treatment).
0.001 to 99.99 parts by weight, preferably 0.001 to 30 parts by weight, based on 100 parts by weight of the raw material of the food or beverage may be added at the time of producing the food or beverage. The effective dose of the alpha-asarone or its salt may be used according to the effective dose of the pharmaceutical composition, but may be less than the above-mentioned range for the purpose of health and hygiene or long-term intake for the purpose of health control, The above components can be used in an amount exceeding the above range because there is no problem in terms of safety.
There is no particular limitation on the kind of the food. The food composition may be used in the form of tablets, hard or soft capsules, liquids, suspensions, and the like, which may contain conventional excipients, such as excipients in the case of oral preparations, Binders, disintegrators, lubricants, solubilizers, suspending agents, preservatives or extenders.
Examples of the food include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums and ice cream, soups, drinks, tea, drinks, , And other nutrients, but are not limited to these kinds of foods.
Alpha-asarone according to the present invention has an effect of enhancing motor function or promoting recovery of injured spinal cord when administered to spinal cord injured individuals, and thus may be useful for preventing, improving or treating inflammatory diseases and spinal cord injuries. In addition, Alpha Asarone is a registered herb medicine ingredient in the Korea Food and Drug Administration and has a low risk of adverse effects. Therefore, it is easy to carry out clinical trials because it is exempted from the nonclinical toxicity and pharmacological test results when obtaining the approval of the drug product.
1 is a schematic diagram showing development of a mouse spinal cord injury model using a weight.
FIG. 2 is a graph showing the results of a BBB score test for measuring the locomotor function of a spinal cord injured subject to which the pharmaceutical composition according to the present invention was administered. As shown in FIG. 2, Of the patients were significantly higher than those of the control group.
FIG. 3 shows a cut-off histological analysis of the injured area of the group administered with the pharmaceutical composition according to the present invention on
FIG. 4 is a graph showing the ratios of arg1, iNOS and CD68 immunohistocytic staining (FIG. 4A) and arg1, iNOS, and CD68 of the control group and the group administered with the pharmaceutical composition according to the present invention on
FIG. 5 is a graph (FIG. 5A) showing the Ang1 and VEGFR immunohistochemical staining images (FIG. 5A) and intensity of the control group (FIG. 5B) of the group administered with the pharmaceutical composition according to the present invention at 14 days after injury of the spinal cord.
Hereinafter, the present invention will be described in more detail with reference to Examples. However, these examples are for illustrative purposes only, and the scope of the present invention is not limited to these examples.
Example 1: alpha-asarone (alpha- asarone ) As an active ingredient in the manufacture of a pharmaceutical composition for preventing or treating spinal cord injury
Alpha asarone was purchased and prepared by stirring 1% carboxymethylcellulose solution and 1% Tween 80.
Thus, a composition for preventing or treating spinal cord injury comprising alpha asarone according to the present invention was prepared, and the effect of treating spinal cord injury using Example 1 was confirmed in the following experimental examples.
Experimental Example 1: Preparation of spinal cord injury animal model and drug administration
1.1. Animal varieties and supply of spinal cord compression model
Sprague Dawley female rats aged 9-11 weeks, 250-300 g, and animals were examined for their breeding and appearance by Orient Bio. After that, breeding was carried out within the scope of the animal ethics committee regulation of the University of Science.
1.2. Animal anesthesia and sacrifice
SD rats (8-10 weeks old) are anesthetized with 1ul of 1: 1 ratio of zoletile (50 mg / kg, Virbac Laboratories, France) and rumun (10 mg / kg, Bayer, Korea) at a ratio of 1: 1. After the end of the experiment, we refer to the euthanasia guideline for euthanasia and guilt for the case and USE OF LABORATORY ANIMALS Eighth Edition.
1.3. Spinal cord compression model (Compression Model)
The spinal cord injury was applied using a fall-fall method. The weight and weights of 20g, 35g, and 50g were used to construct a laryngeal laminectomy at the T10 site to remove the vertebral bone plate. An impactor, which is further coupled to the support rod, causes spinal cord injury. Weights may be used in different weights, and a schematic diagram thereof is shown in Fig.
Specifically, the body weight was first measured, and the epilator was used to epilate in a circle having a radius of about 4 cm around the 10th thoracic vertebra region. The epilating area was sterilized with 70% alcohol. The surgical site was disinfected with povidone and 70% alcohol. After confirming the position of the thoracic 10 (T10), only the surgical site was covered with the exposed sterile surgical catheter, and the epidermis was incised by a surgical knife about 5 cm. The muscle layer exposed after the incision was incised by about 2 cm in the 10th thoracic region using a surgical knife. When the 10th thoracic spinous process was exposed, the extensor was removed using an Offset Bone Nipper (FST, Germany) and the spinal bone plate (lamina) was exposed to the posterior spinal cord without damage to the dura meter. The 8th thoracic and 11th thoracic spiral surgeries were fixed with Allis Forceps to expose the posterior spinal cord without damaging the dura. Then, the spinal cord was squeezed at 10th thoracic position for 5 minutes by using weights (20g, 35g, and 50g) to produce a spinal cord compression model.
1.4. Administration of the pharmaceutical composition
The composition prepared in Example 1 was orally administered at 1 mg / kg of the above 1.3.
1.5. all Experimental group
For the whole experiment, 54 rats were used, and each experimental group was as follows.
Control 1: Positive control [sham] (spinal cord exposure without damage to the dura) = 6 mice
Experimental group 1: Negative control (no treatment, only injury) = 24
Experimental group 2: Injury + alpha-asarone = Oral administration up to 7 days after injury of 24 spinal cord
Experimental Example 2: Behavior analysis _ Rain BBB Open field score test
The BBB score test was performed to measure the motor function of the spinal cord trauma mice administered with the drug.
The BBB score test is a test method that can evaluate various exercise functions in a complex manner. The score is divided from the minimum score of 0 to 21 points when the hind legs can not be used at all according to the 21 items. Which means improved functionality.
From 3 to 14 days after the spinal cord trauma, three skilled subjects observed the movement of the hind legs of each mouse to determine the BBB score and the results are shown in FIG.
As shown in FIG. 1, all mice immediately after the spinal cord trauma showed 0 point with no movement of the hind legs, and after 3 days, the BBB score of the spinal cord injured subjects to which the pharmaceutical composition according to the present invention was administered, Of the total population. The spontaneous recovery was 13.2 ± 7.65 points in the control group after 14 days of spinal cord trauma and 16.4 ± 6.12 points in the spinal cord injured group treated with the pharmaceutical composition according to the present invention. It was confirmed that the function recovery effect was exhibited.
Experimental Example 3: Hematoxylin eosin staining (H & E staining)
The spinal cord of the asarone group (the spinal cord injured population treated with the pharmaceutical composition according to the present invention) and the Injury group (control group) were placed in 4% PFA on
As shown in FIG. 3A, cut-off histological analysis of the injured area of the treated group of the pharmaceutical composition according to the present invention and the control group on
Experimental Example 4: Immunohistochemical staining ( Immunohistochemistry: IHC )
The spinal cord of the asarone group (the spinal cord injured population treated with the pharmaceutical composition according to the present invention) and the Injury group (control group) were placed in 4% PFA on
FIG. 3B shows the results of GFAP immunohistochemical staining of 1 cm of the damaged area of the group administered with the pharmaceutical composition according to the present invention on
FIG. 4 is a graph showing the ratios of arg1, iNOS and CD68 immunohistocytic staining (FIG. 4A) and arg1, iNOS, and CD68 of the control group and the group administered with the pharmaceutical composition according to the present invention on
FIG. 5 is a graph (FIG. 5A) showing the Ang1 and VEGFR immunohistochemical staining images (FIG. 5A) and intensity of the control group (FIG. 5B) of the group administered with the pharmaceutical composition according to the present invention at 14 days after injury of the spinal cord.
As can be seen from FIGS. 3, 4 and 5, in the asazol-treated group, arg1 + / CD68 + was higher than that of the control, and iNOS + / CD68 + was significantly lower. This was more prominent in the 14th day than in the 7th day (Fig. 4B). On the other hand, ANG-1 and VEGFR were higher in asazol-treated group than in control group.
Thus, it was confirmed that the spinal cord injured individuals to which the pharmaceutical composition according to the present invention was administered exhibited a remarkable recovery effect as compared with the control group.
Claims (5)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170129118A KR101986832B1 (en) | 2017-10-10 | 2017-10-10 | Composition for preventing or treating spinal cord injury comprising α-asarone |
| PCT/KR2018/011715 WO2019074235A1 (en) | 2017-10-10 | 2018-10-04 | COMPOSITION CONTAINING α-ASARONE FOR PREVENTION OR TREATMENT OF SPINAL CORD INJURY |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170129118A KR101986832B1 (en) | 2017-10-10 | 2017-10-10 | Composition for preventing or treating spinal cord injury comprising α-asarone |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190040409A KR20190040409A (en) | 2019-04-18 |
| KR101986832B1 true KR101986832B1 (en) | 2019-06-07 |
Family
ID=66101635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170129118A KR101986832B1 (en) | 2017-10-10 | 2017-10-10 | Composition for preventing or treating spinal cord injury comprising α-asarone |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101986832B1 (en) |
| WO (1) | WO2019074235A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110934828A (en) * | 2019-12-25 | 2020-03-31 | 桂林南药股份有限公司 | Asarone oral emulsion and preparation method thereof |
| KR102320780B1 (en) * | 2021-01-29 | 2021-11-02 | 정성삼 | Composition for relieving spinal pain and improving spinal flexibility and method for manufacturing the same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101355483B1 (en) * | 2011-06-15 | 2014-02-05 | 건국대학교 산학협력단 | Pharmaceutical composition and functional food for preventing or treating neurodegenerative disease by Acorus gramineus extracts and Alpha-asarone as effective component |
-
2017
- 2017-10-10 KR KR1020170129118A patent/KR101986832B1/en active IP Right Grant
-
2018
- 2018-10-04 WO PCT/KR2018/011715 patent/WO2019074235A1/en active Application Filing
Non-Patent Citations (2)
| Title |
|---|
| Phytotherapy Research. vol.28, pp.9-21 (2013.03.21.)* |
| 공개특허공보 제10-2012-0138333호(2012.12.26.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019074235A1 (en) | 2019-04-18 |
| KR20190040409A (en) | 2019-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3165228A1 (en) | Female menopause alleviation use of composition containing composite extract of red clover and pomegranate as active ingredient | |
| KR20120059207A (en) | Composition comprising an extact of cordyceps militaris and cordycepin isolated thereform for the improvement and remedial of insomnia | |
| KR101341648B1 (en) | Composition for preventing and treating varicocele or male infertility comprising anthocyanin extracted from black soybean | |
| JP6294710B2 (en) | Glucose metabolism improver | |
| KR101986832B1 (en) | Composition for preventing or treating spinal cord injury comprising α-asarone | |
| JP2023509687A (en) | Composition for prevention or treatment of ocular diseases containing exosomes derived from amniotic epithelial cells as an active ingredient | |
| KR101807953B1 (en) | The pharmaceutical composition for the prevention or treatment of the symptoms in the dementia comprising the extracts from Coriandrum sativum | |
| JPWO2014017570A1 (en) | Composition for preventing or treating osteoarthritis | |
| TW201200137A (en) | Use of isoacteoside or pharmaceutically acceptable salt thereof in inhibiting formation, accumulation or aggregation of amyloid beta peptides, and in fabrication of drug for preventing or treating amyloid beta peptide-associated diseases or conditions | |
| US7875300B2 (en) | Methods for reducing circulating glucose levels | |
| KR102028634B1 (en) | A composition for preventing or treating menopausal cardiovascular disease comprising Cuscuta japonica Chois extract | |
| KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR101636345B1 (en) | Composition for preventing or treating thyroid disorders comprising aloe extracts or fraction thereof | |
| US20190151256A1 (en) | Composition Including Nonanal As Active Ingredient For Preventing Hair Loss Or Stimulating Hair Development | |
| KR101300775B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb１ and Rg３，Compound K，or saponin extract from Panax ginseng as an effective ingredient | |
| KR20190044325A (en) | Composition for preventing or treating spinal cord injury comprising Neutrophil elastase inhibitor | |
| CN115768417A (en) | Muscular atrophy inhibitor | |
| JP2008531552A (en) | Mixed herbal extract of ripening yellow and five peels and composition for prevention and treatment of osteoporosis containing the same as an active ingredient | |
| JP6001789B2 (en) | Use of longan seed alcohol extract | |
| KR101316095B1 (en) | Composition for preventing and treating of neuropathic pain containing ginsenoside Rb１ and Rg３，Compound K，or saponin extract from Panax ginseng as an effective ingredient | |
| Foca et al. | Seeds of horse chestnut (Aesculus hippocastanum L.) and their possible utilization for human consumption | |
| KR20190054772A (en) | Composition for preventing or treating spinal cord injury comprising Matrix Metalloproteinase-8 inhibitor | |
| JP2007291014A (en) | Edible composition having effect of promoting production and release of calcitonin gene-associated peptide | |
| JP6676874B2 (en) | Foods with a function to reduce the risk of developing non-alcoholic fatty liver disease | |
| JP2016537428A (en) | Ephedra arata extract and method of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |